Literature DB >> 3410357

Estrogen and progestin receptor levels as prognosticators for survival in endometrial cancer.

J T Chambers1, N MacLusky, A Eisenfield, E I Kohorn, R Lawrence, P E Schwartz.   

Abstract

The survival of 213 postmenopausal patients with primary endometrial cancer was analyzed as a function of clinicopathologic features and cytosol steroid receptor levels. Estrogen receptor (ER) levels (P = 0.008) and progestin receptor (PR) levels (P = 0.0001) were negatively correlated with grade. ER and PR levels were positively correlated with each other (P = 0.0001), but neither was correlated with age. In 187 patients with stages I and II, ER positivity (greater than or equal to 20 fmole/mg cytosol protein (cp] was statistically associated with grade (P = 0.007); and PR (greater than or equal to 7 fmole/mg cp) was statistically associated with grade (P = 0.001). Univariant analysis revealed that survival for the early endometrial cancer patients was significantly dependent upon ER status (P = 0.0003), PR status (P = 0.0016), and grade (P = 0.0002). Multivariant analysis of ER status, PR status, age, and grade showed that the ER status was a significant prognostic factor for survival (P = 0.0168), even if the positivity of the PR status was defined at greater than or equal to 50 fmole/mg cp. If ER status was divided at 0-19, 20-100, and greater than 100 fmole/mg cp, survival was significantly different between the low range group and the other two groups. If PR status was divided at 0-6, 7-50, and greater than 50 fmole/mg cp survival was significantly different between the first two groups and the high range group. Thus, survival in these endometrial cancer patients was better predicted by ER status than grade.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3410357     DOI: 10.1016/0090-8258(88)90270-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.

Authors:  Kimberly K Leslie; Michael W Sill; Edgar Fischer; Kathleen M Darcy; Robert S Mannel; Krishnansu S Tewari; Parviz Hanjani; Jason A Wilken; Andre T Baron; Andrew K Godwin; Russell J Schilder; Meenakshi Singh; Nita J Maihle
Journal:  Gynecol Oncol       Date:  2013-02-21       Impact factor: 5.482

2.  Loss of progesterone receptor through epigenetic regulation is associated with poor prognosis in solid tumors.

Authors:  Yiyang Li; Cheng Huang; Tamar Kavlashvili; Abby Fronk; Yuping Zhang; Yang Wei; Donghai Dai; Eric J Devor; Xiangbing Meng; Kristina W Thiel; Kimberly K Leslie; Shujie Yang
Journal:  Am J Cancer Res       Date:  2020-06-01       Impact factor: 6.166

3.  Steroid hormone receptors and their clinical significance in cancer.

Authors:  R I Nicholson; R A McClelland; J M Gee
Journal:  J Clin Pathol       Date:  1995-10       Impact factor: 3.411

4.  The prognosis of patients with gastric cancer possessing sex hormone receptors.

Authors:  M Matsui; O Kojima; S Kawakami; Y Uehara; T Takahashi
Journal:  Surg Today       Date:  1992       Impact factor: 2.549

5.  Fatostatin reverses progesterone resistance by inhibiting the SREBP1-NF-κB pathway in endometrial carcinoma.

Authors:  Xiaohong Ma; Tianyi Zhao; Hong Yan; Kui Guo; Zhiming Liu; Lina Wei; Wei Lu; Chunping Qiu; Jie Jiang
Journal:  Cell Death Dis       Date:  2021-05-26       Impact factor: 8.469

6.  Insulin-like growth factors in endometrioid adenocarcinoma: correlation with clinico-pathological features and estrogen receptor expression.

Authors:  Yuan-Jiao Liang; Qun Hao; Hui-Ming Zhang; Yuan-Zhe Wu; Jian-Dong Wang
Journal:  BMC Cancer       Date:  2012-06-21       Impact factor: 4.430

Review 7.  Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.

Authors:  Yanli Zhang; Dong Zhao; Changguo Gong; Fengmei Zhang; Jing He; Wei Zhang; Yulan Zhao; Jing Sun
Journal:  World J Surg Oncol       Date:  2015-06-25       Impact factor: 2.754

8.  Association of body mass index with ER, PR and 14-3-3σ expression in tumor and stroma of type I and type II endometrial carcinoma.

Authors:  Joseph F Peevey; Brandon-Luke L Seagle; Kruti P Maniar; J Julie Kim
Journal:  Oncotarget       Date:  2017-06-27

Review 9.  Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019.

Authors:  Lindsey M Charo; Steven C Plaxe
Journal:  F1000Res       Date:  2019-06-12

10.  Association between RCAS1 expression and clinical outcome in uterine endometrial cancer.

Authors:  K Sonoda; S Miyamoto; T Hirakawa; T Kaku; M Nakashima; T Watanabe; K Akazawa; T Fujita; H Nakano
Journal:  Br J Cancer       Date:  2003-08-04       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.